From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
In the spotlight:
The B.J. Kennedy Geriatric Oncology Award
MediMix is pleased to acknowledge Professor Hans Wildiers from the University Hospital of Leuven for his exceptional achievements in the area of geriatric oncology.
Cindy Kenis, a Nurse Specialist in Geriatric Oncology at the University Hospital of Leuven, presented at ASCO the results of the G-oncoCOACH study during the oral abstract session of the
Highlights from the Clinical Science Symposium
Dr Emiel De Jaeghere selected three interesting highlights from the clinical science symposium on the role of the microbiome in immune checkpoint inhibitor response and resistance. He discussed the potential
ASCO 2023 Plenary Session
During the ASCO 2023 plenary session, we had the privilege of communicating four selected abstracts that showcased groundbreaking advancements in oncology research. These abstracts were carefully chosen for their potential to impact clinical practice and patient outcomes.
The plenary session at ASCO saw Prof Roy S. Herbst of the Yale Cancer Center present the overall survival analysis from the ADAURA trial on adjuvant osimertinib for patients with resected EGFR-mutated stage IB-IIIA
Dr. Pierre Frères of CHU de Liège gives his feedback regarding the INDIGO study presented by Prof. Ingo K. Mellinghoff. This study is a phase 3, double-blinded, global, randomized trial comparing vorasidenib to placebo
Dr. Claudio Cerchione provided commentary on the latest SWOG S1826 study presented by Dr. Alex Francisco Herrera of the City of Hope National Medical Center. This study is focused on a randomized comparison between
Prof Eric Van Cutsem and Prof Deborah Schrag discuss the PROSPECT study. This study is a randomized phase III trial that aims to compare neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of
Latest daily highlights
Dr. Mariana Brandao from the Institut Jules Bordet in Brussels provided insightful commentary on three interesting presentations from the oral abstract session on metastatic non small cell lung cancer.
During the poster discussion session on colon and anal cancer, Prof Dr Eric Van Cutsem from the University Hospital Gasthuisberg, Leuven, offered valuable insights that were informative and relevant.
Dr. Guilherme Nader Marta recently shared his insights on the most noteworthy presentations from the poster discussion session on metastatic breast cancer.
Prof. Dr Anne Demols presented the latest findings from several studies on gastric, pancreatic, and hepatobiliary cancer.
Dr Frères reports in this video on the most exciting presentations during the oral abstract session on kidney and bladder cancer.
Prof. Jean-François Baurain and Prof. Bart Neyns discuss highlights from the oral abstract session on melanoma/skin cancer.
Professor Benjamin Besse and Dr. Mariana Brandao delve deeper into the results of the CHRYSALIS-2 study, which is a phase 1/1b study that aims to evaluate the efficacy of amivantamabam
Prof Els Van Nieuwenhuysen discussed the initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib with or without defactinib in recurrent low-grade serous ovarian cancer,
Prof. Dr. Gontran Verset, an expert in digestive oncology from the Université Libre de Bruxelles, shares the latest findings from various studies presented in the poster discussion session on gastric,
Dr. Elisa Agostinetto, medical oncologist at the Institute Jules Bordet in Brussels shares her highlights from the poster discussion session on local/regional/adjuvant treatment for breast cancer.
With their combined knowledge and experience, Prof. Paul Clement and Prof. Jean-Pascal Machiels offer valuable insights into head & neck cancer research and treatment advancements.
Prof. François Duhoux from Cliniques Universitaires St Luc in Brussels shares his insights on the most exciting presentations in the oral abstract session on metastatic breast cancer.
In this informative video, Prof Denys, engages with Prof Els Van Nieuwenhuysen on two studies presented in a Clinical Science Symposium on the surgical management of gynaecological cancers.
Dr. Laure-Anne Teuwen shared her thoughts on some interesting abstracts presented during the poster discussion session on GU cancer, specifically kidney and bladder.
During a recent update on cancer treatment, Prof. Dr. Hans Prenen, a digestive oncologist at the University Hospital of Antwerp, shared the latest data on various studies.
Dr. Laure-Anne Teuwen, medical oncologist at the university hospital of Antwerp highlighted a population-based study evaluating the prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast
Prof. Christophe Dooms from UZ Gasthuisberg in Leuven discussed several important studies presented at the conference. One of the studies mentioned was the Phase I LIBELULE Study, which is a
In this video, the MIRASOL trial (GOG 3045/ENGOT OV-55) was discussed, focusing on the evaluation of the safety and efficacy of mirvetuximab soravtansine-gynx in comparison to chemotherapy.
During the presentation of the late-breaking abstract on the PEACE-1 study, Dr. Alberto Bossi, a radiation oncologist at Gustave Roussy in Villejuif, Paris, thoroughly discussed the study’s results.
Dr Kristof Cuppens shares his insights on key presentations of ASCO 2023. Dr. Cuppens has provided us with invaluable commentary on significant studies presented at the conference.
Prof. Hannelore Denys from UZ Ghent shared some intriguing findings from the oral abstract session on gynaecologic cancer.
Prof Bertrand Tombal from Cliniques Universitaires St Luc in Brussels was asked by MediMix to choose noteworthy data from the poster discussion session on prostate cancer.
Today marks the start of the ASCO 2023 congress, with the first oral abstract session focusing on local, regional, and adjuvant treatment for breast cancer.
Don’t miss a thing.
Subscribe to our daily mail and get all the latest news from ASCO 2023 from your colleagues.
Daily highlights
In-depth stories
Poster selection